Skip to main content
Top
Published in: International Journal of Clinical Oncology 5/2014

01-10-2014 | Original Article

Expression and prognostic value of Ars2 in hepatocellular carcinoma

Authors: Qian He, Yongde Huang, Lei Cai, Shaobo Zhang, Chenghua Zhang

Published in: International Journal of Clinical Oncology | Issue 5/2014

Login to get access

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Arsenic resistance protein 2 (Asr2) was reported to be important for microRNA (miR) biogenesis, and its depletion could reduce the levels of several miRs, including miR-21, which is over-expressed in HCC. We hypothesized that Ars2 is also overexpressed in HCC and may be involved in the biological properties of HCC.

Methods

Ars2 immunolabeling was evaluated in 132 HCCs. Ars2 immunolabeling, Ars2 qRT-PCR and miR-21 were evaluated in 20 HCCs and in paired normal tissues. Ars2 shRNA was transfected into SMCC-7721 and HepG2 HCC cells. The cell proliferation and expression of Ars2 and miR-21 were subsequently evaluated.

Results

Ars2 was expressed primarily in the nucleus of HCC cells. The expression of Ars2 was statistically correlated with the loss of HCC differentiation and pathological stage. The survival rates of patients with low Ars2 expression in HCC were statistically higher than patients with overexpressed Ars2 in HCC. Ars2 and miR-21 were more highly expressed in HCC specimens than normal tissues, and they were also correlated. The knockdown of Ars2 in HCC cells inhibited miR-21 expression and cell proliferation.

Conclusions

Ars2 is overexpressed in HCC and may have prognostic value; it might play an important role in HCC proliferation and miR-21 expression.
Literature
1.
go back to reference Fares N, Peron JM (2013) Epidemiology, natural history, and risk factors of hepatocellular carcinoma. La Revue du praticien 63:216–217, 220–212 Fares N, Peron JM (2013) Epidemiology, natural history, and risk factors of hepatocellular carcinoma. La Revue du praticien 63:216–217, 220–212
2.
go back to reference Tang ZY (2001) Hepatocellular carcinoma: cause, treatment and metastasis. World J Gastroenterol 7:445–454PubMed Tang ZY (2001) Hepatocellular carcinoma: cause, treatment and metastasis. World J Gastroenterol 7:445–454PubMed
4.
go back to reference Gruber JJ, Zatechka DS, Sabin LR et al (2009) Ars2 links the nuclear cap-binding complex to RNA interference and cell proliferation. Cell 138:328–339PubMedCrossRefPubMedCentral Gruber JJ, Zatechka DS, Sabin LR et al (2009) Ars2 links the nuclear cap-binding complex to RNA interference and cell proliferation. Cell 138:328–339PubMedCrossRefPubMedCentral
5.
go back to reference Sabin LR, Zhou R, Gruber JJ et al (2009) Ars2 regulates both miRNA- and siRNA- dependent silencing and suppresses RNA virus infection in Drosophila. Cell 138:340–351PubMedCrossRefPubMedCentral Sabin LR, Zhou R, Gruber JJ et al (2009) Ars2 regulates both miRNA- and siRNA- dependent silencing and suppresses RNA virus infection in Drosophila. Cell 138:340–351PubMedCrossRefPubMedCentral
7.
go back to reference Gramantieri L, Fornari F, Callegari E et al (2008) MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12:2189–2204PubMedCrossRef Gramantieri L, Fornari F, Callegari E et al (2008) MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12:2189–2204PubMedCrossRef
8.
go back to reference You N, Liu W, Wang T et al (2012) Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo. Oncol Rep 28:2091–2100PubMed You N, Liu W, Wang T et al (2012) Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo. Oncol Rep 28:2091–2100PubMed
9.
go back to reference Matuo MC, de Oliveira Takamoto RT, Kikuchi IS et al (2013) Effect of bixin and norbixin on the expression of cytochrome P450 in HepG2 cell line. Cell Biol Int 37:843–848PubMedCrossRef Matuo MC, de Oliveira Takamoto RT, Kikuchi IS et al (2013) Effect of bixin and norbixin on the expression of cytochrome P450 in HepG2 cell line. Cell Biol Int 37:843–848PubMedCrossRef
10.
go back to reference He Q, Cai L, Shuai L et al (2013) Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21. Mol Carcinog 52:286–296PubMedCrossRef He Q, Cai L, Shuai L et al (2013) Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21. Mol Carcinog 52:286–296PubMedCrossRef
11.
go back to reference Soman G, Yang X, Jiang H et al (2009) MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis. J Immunol Methods 348:83–94PubMedCrossRefPubMedCentral Soman G, Yang X, Jiang H et al (2009) MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis. J Immunol Methods 348:83–94PubMedCrossRefPubMedCentral
12.
go back to reference Andreu-Agullo C, Maurin T (2012) Ars2, an essential player in neural stem cell identity. Med Sci 28:459–462 Andreu-Agullo C, Maurin T (2012) Ars2, an essential player in neural stem cell identity. Med Sci 28:459–462
13.
14.
go back to reference Bentwich I, Avniel A, Karov Y et al (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37:766–770PubMedCrossRef Bentwich I, Avniel A, Karov Y et al (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37:766–770PubMedCrossRef
15.
go back to reference Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20PubMedCrossRef Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20PubMedCrossRef
19.
go back to reference Bhatti I, Lee A, James V et al (2011) Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. J Gastrointest Surg 15:199–208PubMedCrossRef Bhatti I, Lee A, James V et al (2011) Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. J Gastrointest Surg 15:199–208PubMedCrossRef
20.
go back to reference Selaru FM, Olaru AV, Kan T et al (2009) MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49:1595–1601PubMedCrossRefPubMedCentral Selaru FM, Olaru AV, Kan T et al (2009) MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49:1595–1601PubMedCrossRefPubMedCentral
21.
go back to reference Pezzolesi MG, Platzer P, Waite KA et al (2008) Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet 82:1141–1149PubMedCrossRefPubMedCentral Pezzolesi MG, Platzer P, Waite KA et al (2008) Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet 82:1141–1149PubMedCrossRefPubMedCentral
Metadata
Title
Expression and prognostic value of Ars2 in hepatocellular carcinoma
Authors
Qian He
Yongde Huang
Lei Cai
Shaobo Zhang
Chenghua Zhang
Publication date
01-10-2014
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 5/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0642-6

Other articles of this Issue 5/2014

International Journal of Clinical Oncology 5/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine